Safety and Monitoring of Brexpiprazole + Paroxetine Combination

Serotonin Syndrome Risk and Monitoring

The American Academy of Child and Adolescent Psychiatry advises that clinicians should monitor for serotonin syndrome when brexpizole is combined with paroxetine; the risk is substantially lower than when serotonergic agents are paired with MAO inhibitors. 1
Initiation should start at low doses with gradual titration, and patients should be observed closely for serotonin‑syndrome signs during the first 24–48 hours after any dose change. [1][2]3
Typical serotonin‑syndrome manifestations include altered mental status (confusion, agitation, anxiety), neuromuscular hyperactivity (tremor, clonus, hyperreflexia), and autonomic hyperactivity (hypertension, tachycardia, diaphoresis). [1][2]3
Severe presentations may progress to fever, seizures, cardiac arrhythmias, or loss of consciousness requiring hospitalization. [1][2]

Paroxetine has been linked to a higher incidence of suicidal thoughts or behaviors compared with other selective serotonin‑reuptake inhibitors. [1][4]3
Discontinuation syndrome occurs more frequently with paroxetine than with other SSRIs, reflecting its relatively short elimination half‑life. [1][2]4
As a strong CYP2D6 inhibitor, paroxetine can interact with any co‑administered medication that is metabolized by this enzyme, necessitating dose adjustments or alternative agents. [1][4]3

In older adult patients, paroxetine should generally be avoided because of a higher propensity for adverse effects; alternative SSRIs such as escitalopram or sertraline are preferred. 5